<DOC>
	<DOCNO>NCT02655198</DOCNO>
	<brief_summary>In trial , potential anti-epileptic effect low dose fenfluramine Lennox Gastaut epilepsy study . An exploratory dose find add-on trial propose . At baseline end study , ECG ultrasound heart perform part safety follow .</brief_summary>
	<brief_title>Add-on Therapy With Low Dose Fenfluramine Lennox Gastaut Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Lennox Gastaut Syndrome</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>Inclusion criterion Electroclinical epilepsy syndrome compatible Lennox Gastaut syndrome : Minimum requirement ( base ILAE epilepsydiagnosis.org ) : Multiple seizure type include case tonic seizure EEG show slow spike wave abnormal background Abnormal cognitive development MRI compatible Lennox Gastaut epilepsy : progressive disease Drug resistant : least 4 documented seizure last 4 week inclusion ( minimum 4 seizure least 2 separate week ) Seizure type eligible inclusion : generalize tonicclonic seizure GTC , tonic seizure TS , atonic seizure AS clearly recognizable focal seizure FS . &gt; = 2 AEDs ( include VNS ) 4 week inclusion ( change treatment inclusion trial ) Age 3 18 year Subject male nonpregnant , nonlactating female . Female subject childbearing potential must pregnant breastfeeding . Female subject childbearing potential must negative urine pregnancy test . Subjects childbearing childfathering potential must willing use medically acceptable form birth control , include abstinence , treat study 90 day last dose study drug . Exclusion Criteria Known clinical cardiovascular abnormality ( include valvular problem , shunt , pulmonary hypertension , exercise intolerance ) Any cardiac ultrasound/ECG abnormality baseline Weight percentile 3 age baseline Subject receive concomitant therapy : centrallyacting anorectic agent ; monoamine oxidase inhibitor ; centrallyacting compound clinically appreciable amount serotonin agonist antagonist property , include serotonin reuptake inhibition ; atomoxetine , centrallyacting noradrenergic agonist ; cyproheptadine , and/or cytochrome P450 ( CYP ) 2D6/3A4/2B6 inhibitors/substrates . Subject unwilling refrain large daily serving grapefruit and/or Seville orange , juice begin Baseline Period throughout study .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>refractory childhood epilepsy</keyword>
	<keyword>Lennox Gastaut syndrome</keyword>
	<keyword>fenfluramine</keyword>
	<keyword>anti-epileptic treatment</keyword>
</DOC>